RHHBY: Roche Holding insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
70 institutions reported holding $251.77M of Roche Holding on Form 13F (68 the quarter before). 11 opened a new position and 11 sold out. Shares held by institutions: -4%.
| Largest holders | Shares | Value |
|---|---|---|
| Aristotle Capital Management, LLC | 1,970,729 | $101.33M |
| Saratoga Research & Investment Management | 1,188,687 | $61.04M |
| Boston Common Asset Management, LLC | 300,155 | $15.41M |
| OLD NATIONAL BANCORP /IN/ | 287,612 | $14.83M |
| Altrius Capital Management Inc | 190,302 | $9.77M |
| Moran Wealth Management, LLC | 173,426 | $8.91M |
| HUNTINGTON NATIONAL BANK | 117,499 | $6.06M |
| RHUMBLINE ADVISERS | 98,640 | $5.07M |
| KORNITZER CAPITAL MANAGEMENT INC /KS | 61,873 | $3.19M |
| Sterling Capital Management LLC | 60,290 | $3.11M |
Clinical trial readouts
Up to 20 Phase 2 or 3 trials by Roche Holding with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-08-13 | Crovalimab | Paroxysmal Hemoglobinuria, Nocturnal | Phase 1/2 | 59 | Completed | NCT03157635 |
| 2026-08-25 | Giredestrant | Endometrial Cancer | Phase 2 | 33 | Completed | NCT05634499 |
| 2026-08-25 | Zifibancimig | Macular Degeneration | Phase 1/2 | 177 | Completed | NCT04567303 |
| 2026-09-03 | RO7204239 | Obesity | Phase 2 | 285 | Enrollment complete | NCT06965413 |
| 2026-09-17 | Ocrelizumab Test Formulation | Multiple Sclerosis | Phase 2 | 193 | Enrollment complete | NCT07074886 |
| 2026-09-30 (est.) | Entrectinib | Carcinoma, Non-Small-Cell Lung | Phase 3 | 217 | Enrollment complete | NCT04603807 |
| 2026-10-08 (est.) | Tobemstomig | Renal Cell Carcinoma | Phase 2 | 199 | Enrollment complete | NCT05805501 |
| 2026-10-14 (est.) | Atezolizumab | Unresectable Hepatocellular Carcinoma | Phase 3 | 557 | Enrollment complete | NCT04770896 |
| 2026-10-16 (est.) | 89Zr-Df-IAB22M2C | Non-Hodgkins Lymphoma | Phase 1/2 | 211 | Enrollment complete | NCT03533283 |
| 2026-10-19 (est.) | Tobemstomig | Breast Cancer | Phase 2 | 83 | Enrollment complete | NCT05852691 |
| 2026-10-22 (est.) | Ocrelizumab | Progressive Multiple Sclerosis (PMS) | Phase 3 | 927 | Enrollment complete | NCT03523858 |
| 2026-10-28 (est.) | RO7204239 | Spinal Muscular Atrophy (SMA) | Phase 2/3 | 97 | Enrollment complete | NCT05115110 |
| 2026-10-29 (est.) | Afimkibart | Moderately to Severely Active Ulcerative Colitis | Phase 3 | 350 | Enrollment complete | NCT06588855 |
| 2026-10-31 (est.) | Venetoclax | Chronic Lymphocytic Leukemia | Phase 2 | 118 | Enrollment complete | NCT06524375 |
| 2026-11-13 (est.) | Inavolisib | Breast Cancer | Phase 3 | 420 | Recruiting | NCT05646862 |
| 2026-11-18 (est.) | Satralizumab | Duchenne Muscular Dystrophy | Phase 2 | 30 | Enrollment complete | NCT06450639 |
| 2026-11-19 (est.) | RO7269162 | Alzheimer's Disease | Phase 2 | 256 | Enrollment complete | NCT06402838 |
| 2026-11-30 (est.) | Atezolizumab | Cancer | Phase 3 | 382 | Enrollment complete | NCT03148418 |
| 2026-11-30 (est.) | Alectinib | Non-small Cell Lung Cancer | Phase 2 | 99 | Recruiting | NCT04302025 |
| 2026-12-16 (est.) | Satralizumab | NMDAR Autoimmune Encephalitis | Phase 3 | 122 | Enrollment complete | NCT05503264 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.